Cardioprotection with Sildenafil: Implications for Clinical Practice

By  

Current Medicinal Chemistry, Vol. 13, Iss. 26, 2006-11 ,pp. : 3155-3164

Bentham Science Publishers

Access to resources Recommend Favorite

Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

By Lockwood Peter   Ewy Wayne   Hermann David   Holford Nick  

Pharmaceutical Research, Vol. 23, Iss. 9, 2006-09 ,pp. : 2050-2059

Springer Publishing Company

Access to resources Recommend Favorite

A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept

By Ku M. Sherry   Dulin Wendy  

Pharmaceutical Development and Technology, Vol. 17, Iss. 3, 2012-06 ,pp. : 285-302

Informa Healthcare

Access to resources Recommend Favorite

Cardioprotection in the Clinical Setting

By Ivanes Fabrice   Mewton Nathan   Rioufol Gilles   Piot Christophe   Elbaz Meyer   Revel Didier   Croisille Pierre   Ovize Michel  

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 3, 2010-06 ,pp. : 281-287

Springer Publishing Company

Access to resources Recommend Favorite

Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs

By Norman Peter  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 55-66

Informa Healthcare

Access to resources Recommend Favorite